STRS Ohio’s Phathom Pharmaceuticals PHAT Stock Holding History

STRS Ohio’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,100	Closed	-$131K	–	2281
2021 Q3	$131K	Hold	4,100	–	–	﹤0.01%	1885
2021 Q2	$138K	Buy	+4,100	New	+$147K	﹤0.01%	1908
2020 Q3	–	Sell	-2,800	Closed	-$92K	–	2259
2020 Q2	$92K	Hold	2,800	–	–	﹤0.01%	1810
2020 Q1	$72K	Hold	2,800	–	–	﹤0.01%	1733
2019 Q4	$87K	Buy	+2,800	New	+$70.4K	﹤0.01%	1804

Other funds holding PHAT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

STRS Ohio's PHAT Position: Q4 2021 in Review

STRS Ohio sold out of Phathom Pharmaceuticals (PHAT) in Q4 2021, closing a stake of 4,100 shares — an estimated $131K sold.

STRS Ohio first reported a position in PHAT in Q4 2019 and held it in 5 quarters. The position peaked at $138K in Q2 2021. 83 funds tracked by Wall St. Rank hold PHAT as of Q4 2021.

STRS Ohio reported no remaining Phathom Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
STRS Ohio sold 4,100 Phathom Pharmaceuticals shares in Q4 2021, an estimated $131K.
STRS Ohio first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 5 quarters.
STRS Ohio's Phathom Pharmaceuticals position peaked at $138K in Q2 2021.
83 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2021.

Based on STRS Ohio's 13F filing for Q4 2021, filed 24 Jan 2022.